指南与共识其他结缔组织病

2023年美国风湿病学会(ACR)/美国胸科医师学会(CHEST)指南:系统性自身免疫性风湿病患者间质性肺疾病的治疗

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2024-07-08

该指南针对成人系统性自身免疫性风湿病(SARD)相关间质性肺疾病(ILD)的治疗,采用GRADE方法制定循证推荐。共产生35条推荐(含2条强推荐),涵盖一线治疗、一线治疗失败后的进展治疗及快速进展性ILD的治疗。强推荐反对在系统性硬化症相关ILD中一线使用糖皮质激素及进展后使用糖皮质激素;其他SARD的一线ILD治疗则条件性推荐糖皮质激素。

要点

  • 共35条推荐(含2条强推荐),覆盖SARD-ILD一线治疗、进展后治疗及快速进展性ILD治疗。
  • 强推荐反对在系统性硬化症-ILD中一线使用糖皮质激素,也反对进展后使用。
  • 其他所有SARD的一线ILD治疗均条件性推荐糖皮质激素。

核心结论

  • 该临床实践指南是ACR与CHEST首次联合认可的系统性自身免疫性风湿病(SARD)患者间质性肺疾病(ILD)治疗推荐。

研究设计与样本

  • 制定机构为美国风湿病学会(ACR)与美国胸科医师学会(CHEST),方法为基于系统文献综述、采用GRADE方法评级证据,并由临床医生与患者小组共识确定推荐方向与强度。

主要发现

  • 共产生35条推荐,其中包含2条强推荐,覆盖SARD-ILD一线治疗、一线ILD治疗失败后的进展治疗及快速进展性ILD的治疗。
  • 强推荐反对在系统性硬化症-ILD中一线使用糖皮质激素作为ILD治疗,也反对在ILD进展后使用糖皮质激素。
  • 除此之外,其他所有SARD的一线ILD治疗均条件性推荐糖皮质激素。

关键数值与推荐

  • 强推荐:反对在系统性硬化症-ILD中一线使用糖皮质激素作为ILD治疗。
  • 强推荐:反对在系统性硬化症-ILD进展后使用糖皮质激素。
  • 条件性推荐:糖皮质激素用于其他所有SARD的一线ILD治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). METHODS: We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations. RESULTS: Thirty-five recommendations were generated (including two strong recommendations) for first-line SARD-ILD treatment, treatment of SARD-ILD progression despite first-line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis-ILD as a first-line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first-line ILD treatment in all other SARDs. CONCLUSION: This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken). 2024. PMID: 38973731. doi:10.1002/acr.25348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。